Recent studies on adult neural stem cells and the developmental biology of myelination have generated the expectation that neural precursors can repair the damaged central nervous system of multiple sclerosis patients where the endogenous remyelination process has failed. As a result, many laboratories are engaged in translational studies in which the goal is to design ways to promote remyelination and repair. Here we raise issues highlighted by prior experimental and human work that should be considered lest these studies become "lost in translation."
Myelination of nerve fibers is a remarkable evolutionary acquisition of vertebrates, with the confinement of voltage-dependent sodium channels to the small gap-the node of Ranvier-between myelin internodes allowing fast "saltatory" conduction of action potentials. The most common disease of myelin, multiple sclerosis (MS), is an inflammatory demyelinating disease that often starts in young adults and can over subsequent decades follow a chronic progressive course associated with major disability. While therapies designed to reduce inflammation can decrease the disease burden, they do not directly address the question of myelin repair in chronic disease. Recent advances in the stem cell field, and in particular the biology of adult neural precursor cells, have raised hopes that remyelinating therapies may soon be developed, as these cells enable the turnover or addition of differentiated cells in specific regions of the brain. The premise of this minireview is that ongoing translational studies designed to promote repair by harnessing or replacing these cells, while timely, need to consider a series of questions raised by recent work if they are to be successful in their goal of leading to novel therapies for MS.
Historically, the case for promoting remyelination rested on the improvement in conduction efficiency conferred by the switch from nonsaltatory conduction along demyelinated axons to saltatory conduction along a remyelinated axon. However, the more recent appreciation of axon loss as the major pathological cor- relate of progressive functional deterioration in MS has created an even more compelling case. Axons can be damaged in the acute inflammatory phase of the disease or as a result of being chronically demyelinated (Figure 1) . The evidence for the crucial role of the myelin sheath in long-term axon survival comes from knockout mice lacking oligodendrocyte-specific genes. For example, mice defective in the myelin protein gene proteolipid protein have progressive axonal degeneration associated with impaired fast axonal transport, even though the axons are surrounded by loosely compacted myelin (Edgar et al., 2004 ). More surprising is the phenotype of mice deficient in cyclic nucleotide phosphodiesterase (CNP). This gene is expressed in oligodendrocytes. However, the phenotypic consequences are not in these cells, which form normal-looking myelin, but are instead in the underlying axons that undergo severe degeneration, accumulate amyloid precursor protein, and lead to a motor deficit at 7 months (Lappe-Siefke et al., 2003). It is clear from studies such as these that axons in myelinated tracts are dependent on molecularly "fit" oligodendrocytes to maintain their integrity. Elucidating the precise molecular mechanisms is a critical issue to be resolved and will in all likelihood involve the points of contact between the myelin sheath and the axons that occur at the paranode.
An important implication of this work is that longterm axon protection needs to be considered a primary goal of remyelination. How much remyelination is required to achieve this goal remains unknown. It is reasonable to assume that the number of internodes lost and the length of time the axon remains demyelinated will determine the vulnerability of that axon to degeneration. Therefore, efficient remyelination will reduce chronic axonal loss, a view supported by the relative sparing of axons in areas of remyelination compared to areas of demyelination (Kornek et gen, even though there is no evidence that MS is triggered by a similar mechanism. Such "disease models" are clearly necessary as part of the final preclinical testing of proremyelination interventions. However, faced with a complex and diverse disease, an initial, more reductionist type of model is required that permits the detailed dissection of specific disease mechanisms. Such "mechanism models" are especially useful for understanding the cell and molecular biology of remyelination, as illustrated by the extensive use of models based on direct injection of lysolecithin or ethidium bromide into white matter to kill myelin-forming glia. In these models, the acute process of demyelination has a clear temporal separation from the subsequent repair process allowing the specific roles played by individual molecules in repair to be studied. By contrast, in EAE the two processes occur simultaneously in the CNS, making it difficult to separate an effect that renders the environment less hostile to remyelination, allowing it to proceed unhindered, from an effect that truly makes remyelination more effective. Diverse though these models are, they do not cover the full spectrum of pathological manifestations of MS. Within the category of mechanism models, the need for a model of oligodendrocyte apoptosis is highlighted by the recognition that this can be an important cause of pathology in some subgroups of MS ( There is also a critical need for new models that better bridge the gap between disease pathology and the clinical assessments used in MS. A logical choice would be optic neuritis, which is often the first clinical presentation in MS and can be associated with lesions detected by Gadolinium-enhanced magnetic resonance imaging that reflect inflammation. Anatomically localized EAE models (Kerschensteiner et al., 2004) are also potentially valuable, especially if they can be used in primates. The application of imaging techniques such as serial magnetization transfer, able to provide details on demyelination, axonal loss, and/or nerve atrophy in MS, and diffusion tensor imaging that can distinguish axon loss from myelin damage to these rodent and primate models would provide an excellent translational system for the analysis of both drug-and cell-based proremyelination therapies. The broad philosophy behind the quest for proremyelination therapies is the belief that by studying the mechanisms of myelination and remyelination it will be possible to identify key factors whose activation or inhibition will lead to the process proceeding more efficiently. Remyelination requires the recruitment of precursor cells, their differentiation into myelin-forming oligodendrocytes, and the axo-glial interactions that create the sheath. This process is regulated by a complex network of factors derived from neural and immune cells and occurs in response to the unpredictable pathological process of demyelination (Figure 1) . It therefore differs from the tight spatial and temporal genetic program characteristic of myelination. It would make biological sense for the degree of redundancy to be greater in remyelination than myelination, as it would provide a more secure system if several alternative pathways can achieve repair. This concept has important implications for remyelination therapies. First, remyelination failure is unlikely to be the fault of a single factor but instead arises because of disturbances in the controlled regulation of the many factors required to orchestrate remyelination-this is the "dysregulation hypothesis" of remyelination failure (Franklin, 2002) . Second, while a strategy designed to activate a single redundant pathway could still have an effect on repair, inhibiting a single signaling pathway within a redundant network may be inefficient. Therefore the most effective strategies will be those that target the least redundant pathways.
In the search for these targets, much previous attention has focused on molecules on the cell surface or the extracellular environment. Developmental studies have told us a great deal about how these factors control precursor proliferation, migration, and differentiation, and in the considerably smaller number of studies on remyelination, a few individual molecules have been shown to play a role in both development and repair. 
Conclusions
Axons can be damaged in MS during the acute inflammatory phase of the disease or as a result of being chronically demyelinated. Remyelination in MS has the capacity to reduce the latter damage and so alleviate the chronic progressive nature of the disease and as anti-inflammatory treatments become more effective in controlling the acute disease it will become a therapeutic priority. With appropriate use of different animal models, careful consideration of the practicalities and potential benefits of cell therapies, and exploration of multiple targets for drug therapies, we believe that remyelinating therapies will emerge (Figure 1 ). However, they remain an extremely challenging objective, and a realistic appraisal of the timescale required for their development is an important message for myelin biologists to make to the MS community.
